GERARDO MAZZELLA
GERARDO MAZZELLA
Clinical Atrial Fibrillation| Volume 15, ISSUE 7, P971-979, July 01, 2018
Purchase
Subscribe
Save
Share
Reprints
Request
Gerardo MAZZELLA with his friends
Does the CHA2DS2-VASc score reliably predict atrial arrhythmias? Analysis of a nationwide database of remote monitoring data transmitted daily from cardiac implantable electronic devices
Giovanni Rovaris, MD
Francesco Solimene, MD
Antonio D'Onofrio, MD
Daniele Giacopelli, MSc
Alessio Gargaro, MSc
Ennio C. Pisanò, MD
Show all authors
Published:February 22, 2018DOI:https://doi.org/10.1016/j.hrthm.2018.02.023
PlumX Metrics
Previous ArticleRhythm management in myotonic dystrophy: Progres …
Next ArticlePulmonary vein activity does not predict the outcome of c …
Keywords
References
Article Info
Related Articles
Background
CHA 2DS 2-VASc is a validated score for predicting stroke in patients with atrial fibrillation (AF).
Objective
The purpose of this study was to assess whether the CHA 2DS 2-VASc score can predict new-onset AF in a cohort of patients with a cardiac implantable electronic device (CIED) followed with remote monitoring.
Methods
Using the database of the Home Monitoring Expert Alliance project, we selected 2410 patients with no documented AF who had received a CIED with diagnostics on atrial high rate episodes (AHREs). The primary endpoint was time to first day with cumulative AHRE burden ≥15 minutes, 5 hours, 24 hours, and ≥7 consecutive days.
Results
During a median duration of 24.1(11.5–42.9) months, the incidence of AHRE increased with increasing CHA 2DS 2-VASc. At 6 years, occurrence of ≥15-minute AHRE was 80.2% (CHA 2DS 2-VASc ≤1) vs 93.7% (CHA 2DS 2-VASc ≥5), whereas ≥5-hour AHRE incidence was 68.4% (CHA 2DS 2-VASc ≤1) vs 92.5% (CHA 2DS 2-VASc ≥5). Occurrence of ≥24-hour and ≥7-day AHREs also increased with increasing CHA 2DS 2-VASc: 9.1% and 3.9% (CHA 2DS 2-VASc ≤1) vs 40.4% and 28.7% (CHA 2DS 2-VASc ≥5), respectively. Adjusted hazard ratio for unitary CHA 2DS 2-VASc increase ranged from 1.09 (confidence interval 1.04–1.14; P <.001) with AHRE burden ≥15 minutes to 1.26 (confidence interval 1.11–1.42; P <.001) with AHRE burden ≥7 days. At receiver operating curve analysis, CHA 2DS 2-VASc ≥2 was estimated to predict persistent forms of AHREs with 95.8% sensitivity but 11.7% specificity at 3 years. CHA 2DS 2-VASc ≥5 had 77.0% specificity but 34.6% sensitivity.
Conclusion
In a CIED population with no previous diagnosis of clinical AF, AHRE incidence increased with increasing CHA 2DS 2-VASc score. The association was stronger with longer AHREs, but the accuracy of CHA 2DS 2-VASc as AHRE predictor was moderate.
Keywords
Atrial fibrillation
Cardiac implantable electronic device
CHA2DS2-VASc score
Clinical predictor
Remote monitoring
To read this article in full you will need to make a payment
Purchase one-time access
Subscribe to Heart Rhythm
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Wolf P.A.
Abbott R.D.
Kannel W.B.
Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study.
Arch Intern Med. 1987; 147: 1561-1564
View in Article
Scopus (1188)
PubMed
Crossref
Google Scholar
Mattle H.P.
Long-term outcome after stroke due to atrial fibrillation.
Cerebrovasc Dis. 2003; 16: 3-8
View in Article
Scopus (30)
PubMed
Crossref
Google Scholar
Lin H.J.
Wolf P.A.
Kelly-Hayes M.
Beiser A.S.
Kase C.S.
Benjamin E.J.
D'Agostino R.B.
Stroke severity in atrial fibrillation. The Framingham Study.
Stroke. 1996; 27: 1760-1764
View in Article
Scopus (926)
PubMed
Crossref
Google Scholar
Lip G.Y.
Nieuwlaat R.
Pisters R.
Lane D.A.
Crijns H.J.
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation.
Chest. 2010; 137: 263-272
View in Article
Scopus (3508)
PubMed
Abstract
Full Text
Full Text PDF
Google Scholar
Kirchhof P.
Benussi S.
Kotecha D.
et al.
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
Eur Heart J. 2016; 37: 2893-2962
View in Article
Scopus (3238)
PubMed
Crossref
Google Scholar
Nasir J.M.
Pomeroy W.
Marler A.
Hann M.
Baykaner T.
Jones R.
Stoll R.
Hursey K.
Meadows A.
Walker J.
Kindsvater S.
Predicting Determinants of Atrial Fibrillation or Flutter for Therapy Elucidation in Patients at Risk for Thromboembolic Events (PREDATE AF) Study.
Heart Rhythm. 2017; 14: 955-961
View in Article
Scopus (46)
PubMed
Abstract
Full Text
Full Text PDF
Google Scholar
Saliba W.
Gronich N.
Barnett-Griness O.
Rennert G.
Usefulness of CHADS2 and CHA2DS2-VASc scores in the prediction of new-onset atrial fibrillation: a population-based study.
Am J Med. 2016; 129: 843-849
View in Article
Scopus (47)
PubMed
Abstract
Full Text
Full Text PDF
Google Scholar
Slotwiner D.
Varma N.
Akhar J.G.
et al.
HRS Expert Consensus Statement on remote interrogation and monitoring for cardiovascular implantable electronic devices.
Heart Rhythm. 2015; 12: e69-e100
View in Article
Scopus (168)
PubMed
Abstract
Full Text
Full Text PDF
Google Scholar
He Y.
Missing data analysis using multiple imputation: getting to the heart of the matter.
Circ Cardiovasc Qual Outcomes. 2010; 3: 98-105
View in Article
Scopus (127)
PubMed
Crossref
Google Scholar
Heagerty P.J.
Lumley T.
Pepe M.S.
Time-dependent ROC curves for censored survival data and a diagnostic marker.
Biometrics. 2000; 56: 337-344
View in Article
Scopus (1154)
PubMed
Crossref
Google Scholar
Curtis A.B.
Hattoum A.
The who, how, and why of screening patients for atrial fibrillation: More questions than answers.
Heart Rhythm. 2017; 14: 962-963
View in Article
Scopus (1)
PubMed
Abstract
Full Text
Full Text PDF
Google Scholar
Guerra F.
Scappini L.
Maolo A.
Campo G.
Pavasini R.
Shkoza M.
Capucci A.
CHA2DS2-VASc risk factors as predictors of stroke after acute coronary syndrome: a systematic review and meta-analysis.
Eur Heart J Acute Cardiovasc. 2016; ([Epub ahead of print])
View in Article
Scopus (5)
PubMed
Crossref
Google Scholar
Mitchell L.B.
Southern D.A.
Galbraith D.
Ghali W.A.
Knudtson M.
Wilton S.B.
APPROACH Investigators. Prediction of stroke or TIA in patients without atrial fibrillation using CHADS2 and CHA2DS2-VASc scores.
Heart. 2014; 100: 1524-1530
View in Article
Scopus (101)
PubMed
Crossref
Google Scholar
Ricci R.P.
Glotzer T.V.
Home screening for detecting subclinical atrial fibrillation.
J Atr Fibrillation. 2015; 8: 1326
View in Article
PubMed
Google Scholar
Glotzer T.V.
Daoud E.G.
Wyse D.G.
Singer D.E.
Ezekowitz M.D.
Hilker C.
Miller C.
Qi D.
Ziegler P.D.
The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: the TRENDS study.
Circ Arrhythm Electrophysiol. 2009; 2: 474-480
View in Article
Scopus (519)
PubMed
Crossref
Google Scholar
Healey J.S.
Connolly S.J.
Gold M.R.
et al.
Subclinical atrial fibrillation and the risk of stroke.
N Engl J Med. 2012; 366: 120-129
View in Article
Scopus (1124)
PubMed
Crossref
Google Scholar
Mabo P.
Victor F.
Bazin P.
Ahres S.
Babuty D.
Da Costa A.
Binet D.
Daubert J.C.
COMPAS Trial Investigators
A randomized trial of long-term remote monitoring of pacemaker recipients (the COMPAS trial).
Eur Heart J. 2012; 33: 1105-1111
View in Article
Scopus (179)
PubMed
Crossref
Google Scholar
Ricci R.P.
Vaccari D.
Morichelli L.
et al.
Stroke incidence in patients with cardiac implantable electronic devices remotely controlled with automatic alerts of atrial fibrillation. A sub-analysis of the HomeGuide study.
Int J Cardiol. 2016; 219: 251-256
View in Article
Scopus (7)
PubMed
Abstract
Full Text
Full Text PDF
Google Scholar
Martin D.T.
Bersohn M.M.
Waldo A.L.
Wathen M.S.
Choucair W.K.
Lip G.Y.
Ip J.
Holcomb R.
Akar J.G.
Halperin J.L.
IMPACT Investigators. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with implanted defibrillator and cardiac resynchronization devices.
Eur Heart J. 2015; 36: 1660-1668
View in Article
Scopus (179)
PubMed
Crossref
Google Scholar
Botto G.L.
Padeletti L.
Santini M.
et al.
Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events.
J Cardiovasc Electrophysiol. 2009; 20: 241-248
View in Article
Scopus (267)
PubMed
Crossref
Google Scholar
Van Gelder I.C.
Healey J.S.
Crijns H.J.G.M.
Wang J.
Hohnloser S.H.
Gold M.R.
Capucci A.
Lau C.P.
Morillo C.A.
Hobbelt A.H.
Rienstra M.
Connolly S.J.
Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT.
Eur Heart J. 2017; 38: 1339-1344
View in Article
Scopus (167)
PubMed
Crossref
Google Scholar
Lopes R.D.
Alings M.
Connolly S.J.
et al.
Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial.
Am Heart J. 2017; 189: 137-145
View in Article
Scopus (93)
PubMed
Abstract
Full Text
Full Text PDF
Google Scholar
Kirchhof P.
Blank B.F.
Calvert M.
Camm A.J.
Chlouverakis G.
Diener H.C.
Goette A.
Huening A.
Lip G.Y.H.
Simantirakis E.
Vardas P.
Probing oral anticoagulation in patients with atrial high rate episodes: rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
Am Heart J. 2017; 190: 12-18
View in Article
Scopus (83)
PubMed
Abstract
Full Text
Full Text PDF
Google Scholar
Swiryn S.
Orlov M.V.
Benditt D.G.
DiMarco J.P.
Lloyd-Jones D.M.
Karst E.
Qu F.
Slawsky M.T.
Turkel M.
Waldo A.L.
RATE Registry Investigators
Clinical implications of brief device-detected atrial tachyarrhythmias in a cardiac rhythm management device population: results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes.
Circulation. 2016; 134: 1130-1140
View in Article
Scopus (56)
PubMed
Crossref
Google Scholar
Article Info
Publication History
Published online: February 22, 2018
Footnotes
Data collection and analysis were performed in the framework of the Home Monitoring Expert Alliance (HMEA), an investigator-initiated nationwide repository of data. Technical and logistical support necessary for this research was provided by BIOTRONIK Italia, which is not the sponsor of the study and does not provide grants or fees per patient. Mr. Giacopelli and Mr. Gargaro are employees of BIOTRONIK Italia. All other authors have reported that they have no conflicts relevant to the contents of this paper to disclose.
Identification
DOI: https://doi.org/10.1016/j.hrthm.2018.02.023
Copyright
© 2018 Published by Elsevier Inc. on behalf of Heart Rhythm Society.
ScienceDirect
Access this article on ScienceDirect
Related Articles
European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on risk assessment in cardiac arrhythmias: use the right tool for the right outcome, in the right population
Heart Rhythm
In Brief
Full-Text
Open Access
2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: Executive summary
Heart RhythmVol. 13Issue 4
In Brief
Full-Text
2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy
Heart RhythmVol. 16Issue 11
In Brief
Full-Text
2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay
Heart RhythmVol. 16Issue 9
In Brief
Full-Text
2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
Heart RhythmVol. 15Issue 10
In Brief
Full-Text
EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication
Heart RhythmVol. 14Issue 1
In Brief
Full-Text
2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia
Heart RhythmVol. 13Issue 4
In Brief
Full-Text
2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation
Heart RhythmVol. 16Issue 8
In Brief
Full-Text
2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation
Heart RhythmVol. 14Issue 10
In Brief
Full-Text
Open Access
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias
Heart RhythmVol. 17Issue 1
In Brief
Full-Text
Open Access
Comments
Post a Comment